Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Robert O. Cook.
Headache | 2008
Stephen B. Shrewsbury; Robert O. Cook; Glyn Taylor; Ceri Edwards; Nabih M. Ramadan
Objective.— We investigated the pulmonary absorption of dihydroergotamine (DHE) mesylate and compared the safety, pharmacokinetic, and metabolic profile of 4 different doses of orally inhaled DHE delivered by the Tempo™ Inhaler (MAP Pharmaceuticals Inc., Mountain View, CA, USA) with 1.0 mg intravenously (IV) administered DHE in 18 healthy subjects.
Headache | 2009
Robert O. Cook; Stephen B. Shrewsbury; Nabih M. Ramadan
Background.— MAP0004 is a novel orally inhaled formulation of dihydroergotamine mesylate (DHE) currently in development that has been clinically observed to provide rapid (∼10 minutes) therapeutic levels of DHE but with lower rates of adverse effects (dizziness, nausea, and paresthesia) compared with intravenous (IV) dosing. Receptor‐based mechanistic studies were conducted to determine if differences between IV DHE and inhaled DHE (MAP0004) binding and functional activity were responsible for the improved adverse event profile.
Archive | 2008
Robert O. Cook; Stephen B. Shrewsbury; Nabih N. Ramadan; Thomas A. Armer
Archive | 2009
Thomas A. Armer; Robert O. Cook; Terry Alfredson; Anthony Sun
Archive | 2012
Robert O. Cook; Jian Zhang; Thomas A. Armer
Archive | 2010
Robert O. Cook; Thomas A. Armer; Sergey Alexandrovich Kosarev; Dejian Xie
Archive | 2012
Robert O. Cook; Jian Zhang; Thomas A. Armer
Archive | 2010
Jian Zhang; Robert O. Cook; Thomas A. Armer; Sergey Alexandrovich Kosarev; Dejian Xie
Archive | 2009
Robert O. Cook; Thomas A. Armer
Archive | 2010
Robert O. Cook; Veronica S. De Guzman; Thomas A. Armer; Timothy S. Nelson
Collaboration
Dive into the Robert O. Cook's collaboration.
